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OBJECTIVE: Medication non-adherence is already a signiﬁcant
problem for patients with schizophrenia, possibly exacerbated by
medication copayments increases from $2 to $7 (2002). From the
VA’s perspective, such health policy decisions balance ﬁnancial
beneﬁts with unintended cost-related adherence consequences.
This study examines the cost-offset of copayment revenue
versus higher inpatient and emergency department (ER) costs.
METHODS: Pharmacy prescriptions, health services utilization,
and VA costs for all veterans (N = 69,986) diagnosed with
schizophrenia were analyzed 33 months Pre and Post policy
change. We calculated additional copayment revenue versus uti-
lization costs (1999 adjusted dollars), contrasting veterans
subject to copayment increases with a natural control group of
exempt patients. RESULTS: In comparison to the pre-policy
period and exempt patients, total prescriptions for copayment
veterans (N = 33,431) continued increasing slightly after the
copayment change, but psychotropic ﬁlls dropped 18%. Psychi-
atric admissions and hospital days rose 4%, reversing downward
trends. Higher copayments yielded $17.3 million in additional
revenue, but higher pharmacy costs of $5.5 million. Inpatient
and ER costs increased $13.3 million and $0.6 million, respec-
tively. Therefore, the VA’s net cost-beneﬁt revenue change was
negative $2.1 million, or $745,000 annualized losses. Sensitivity
analyses altering utilization costs and the proportion of post-
policy changes due to higher copayments produced annualized
cost-beneﬁts ranging from -$1.4 million to $0.3 million. CON-
CLUSION: This descriptive study suggests that the policy change
translated into greater copayment revenue while dampening
overall pharmacy cost increases. However, unanticipated conse-
quences included sharply reduced psychotropic ﬁlls leading to
poorer adherence and higher utilization. Recognizing complex
causal assumptions, the VA nevertheless appeared to experience
ﬁnancial losses at the expense of clinical ramiﬁcations. Policy
changes targeting pharmacy beneﬁts for vulnerable psychiatric
patients should be implemented carefully, recognizing trade-offs
between ﬁnancial gains and costs associated with clinical dete-
rioration. Longer term studies are needed to gauge sustained
effects as veterans reconcile behaviors with higher medication
expenses.
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OBJECTIVE: To compare the cost impact of real-world versus
guideline recommended dosing of second generation antipsy-
chotics (SGAs) in treating schizophrenia. METHODS: A retro-
spective cohort analysis was conducted on a commercially-
insured population (Pharmetrics data 2000–2006) to determine
the real-world frequency distribution of SGA monotherapy doses
in patients aged 18–64 with schizophrenia with at least 90 days
of continuous SGA monotherapy. We also determined the fre-
quency distribution within the dosing ranges recommended in
the 2004 American Psychiatric Association (APA) Practice
Guideline for Schizophrenia. Average daily dose was calculated
based on the last prescription during a 6-month post-index
follow-up period. Based on these dosing distributions, acquisi-
tion costs for each SGA were estimated using the 2007 wholesale
list price. A sensitivity analysis was conducted to examine
the impact of different distribution assumptions for APA-
recommended doses on pharmacy cost impact. RESULTS: The
mean per-patient-per month (PPPM) costs for the real world
(median dose) and APA-recommended dose range were: aripipra-
zole US$434 (15 mg/day) and US$382 (10–30 mg/day); quetiap-
ine US$355 (300 mg/day) and US$460 (300–800 mg/day);
risperidone US$293 (3 mg/day) and US$315 (2–8 mg/day); olan-
zapine US$414 (10 mg/day) and US$447 (10–30 mg/day);
ziprasidone US$372 (120 mg/day) and US$354(120–200 mg/
day). All cost differences were signiﬁcant (p < 0.01). Various
types of distribution for APA-recommended doses were exam-
ined and the pharmacy cost impact did not signiﬁcantly change
following a sensitivity analysis. CONCLUSION: When dosed
within APA-recommended ranges, per-patient SGA costs differ
from that of real-world dosing. Underdosing of certain SGAs
may lead to an inaccurate perception of a lower relative cost
compared to other SGAs.
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OBJECTIVE: To compare the economic outcomes of 3 hypo-
thetical cohorts of schizophrenic patients receiving 3 different
antipsychotic agents over 6 weeks and 12 months from a public
hospital perspective of Hong Kong METHODS: Three hypo-
thetical cohorts of 100 patients were given paliperidone 6 mg
(PP), olanzapine 10 mg (OL) and quetiapine 750 mg (QT) for
acute exacerbation of schizophrenia. A decision analytic model
was used to project the economic outcomes 6 weeks and 12
months after the start of therapy. The categories of inputs
required in populating the model were: characteristics of relapse,
rates of adverse effects, health care resource utilization, unit costs
of health care resources, and switch rate to other oral atypical
antipsychotics. Published randomized controlled trial data were
used for obtaining response rates of the three drugs. Published
data from long-term clinical trials were adopted for rates of
discontinuation, switching, relapse and adverse events in the
model. Cost of hospitalization, drug costs and other laboratory
procedural costs were obtained from the available information of
the local health authority. Other unit costs of health care resource
data were from published information of the government. Sen-
sitivity analyses were performed on the key parameters to test the
robustness of the results. RESULTS: Several conservative
approaches were adopted in data analysis. The overall costs of
treatment per patient were: US$169(PP), US$235(OL), and
US$225(QT) after 6 weeks; and US$5505(PP), US$5576(OL),
and US$5809(QT) after 12 months. Sensitivity analyses of the
key parameters had no effects on the results. CONCLUSION: In
the public hospital setting in Hong Kong, estimation using a
decision analytic model revealed that the overall cost of treat-
ment using PP for schizophrenic patients with acute exacerbation
appears to be less than OL and QT both 6 weeks and 12 months
after therapy.
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